VISTA As a Mediator of Immune Suppression in AML Initiated By DNMT3A and NPM1 mutations
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-206063
Abstract: In an immunocompetent host, cancer cells must overcome the immune response to develop into a clinically recognizable tumor. Although “tumor immune escape” mechanisms have been extensively studied in solid tumors (and successful immunotherapies have been… read more here.
Keywords: dnmt3a npm1; npm1 mutations; aml; cell ... See more keywords
DNMT3A and NPM1 co-mutations in Acute Myeloid Leukemia (AML): A genomic landscape study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1722
Abstract: Background: Independent genomic alterations (GA) in the DNMT3A and NPM1 genes occur frequently in AML. While NPM1 mutation carries favorable prognosis in AML and has emerged as a target for anti-menin based treatments, co-mutation with… read more here.
Keywords: mut; dnmt3a npm1; aml; aml cases ... See more keywords
Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML.
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood.2018862383
Abstract: FLT3, DNMT3A, and NPM1 are the most frequently mutated genes in cytogenetically normal acute myeloid leukemia (AML), but little is known about how these mutations synergize upon co-occurrence. Here we show that triple-mutated AML is… read more here.
Keywords: cell; triple mutated; dnmt3a npm1; mutated aml ... See more keywords